Standard Biotools (LAB) Revenue (2010 - 2026)

Standard Biotools (LAB) has 17 years of Revenue data on file, last reported at $21.1 million in Q1 2026.

• On a quarterly basis, Revenue rose 4.57% year-over-year to $21.1 million in Q1 2026; TTM through Mar 2026 was $86.3 million, a 3.71% decrease from a year earlier, with the FY2025 full-year figure at $85.3 million, down 6.24% from the prior year.
• Revenue for Q1 2026 stood at $21.1 million, down from $23.8 million in the prior quarter.
• Over the last five years, Revenue for LAB reached as high as $45.5 million in Q1 2024 and fell as low as $18.8 million in Q2 2022.
• Historically, Revenue has averaged $25.0 million across 5 years, with a median of $24.8 million in 2024.
• Across the five-year window, Revenue sank 72.22% in 2022 and jumped 81.3% in 2024, its largest moves.
• Year by year, Revenue stood at $27.0 million in 2022, then grew by 4.32% to $28.2 million in 2023, then dropped by 12.1% to $24.8 million in 2024, then retreated by 3.96% to $23.8 million in 2025, then decreased by 11.13% to $21.1 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $21.1 million in Q1 2026, $23.8 million in Q4 2025, and $19.6 million in Q3 2025.